Abstract:Purpose: In an earlier study we found normal adeno-associated viral vector type 2 (AAV2)-mediated GFP expression after intravitreal injection to one eye of normal C57BL/6J mice. However, GFP expression was very poor in the partner eye of the same mouse if this eye received an intravitreal injection of the same vector one month after the initial intravitreal injection. We also found both injections worked well if they were subretinal. In this study, we tested whether the efficiency of subretinal AAV vector transduction is altered by a previous intravitreal injection in the partner eye and more importantly whether therapeutic efficiency is altered in the rd12 mouse (with a recessive RPE65 mutation) after the same injection series. Methods: One microl of scAAV5-smCBA-GFP (1 x 10(13) genome containing viral particles per ml) was intravitreally injected into the right eyes of four-week-old C57BL/6J mice and 1 microl of scAAV5-smCBA-hRPE65 (1 x 10(13) genome containing viral particles per ml) was intravitreally injected into the right eyes of four-week-old rd12 mice Four weeks later, the same vectors were subretinally injected into the left eyes of the same C57BL/6J and rd12 mice. Left eyes of another cohort of eight-week-old rd12 mice received a single subretinal injection of the same scAAV5-smCBA-hRPE65 vector as the positive control. Dark-adapted electroretinograms (ERGs) were recorded five months after the subretinal injections. AAV-mediated GFP expression in C57BL/6J mice and RPE65 expression and ERG restoration in rd12 mice were evaluated five months after the second subretinal injection. Frozen section analysis was performed for GFP fluorescence in C57BL/6J mice and immunostaining for RPE65 in rd12 eyes. Results: In rd12 mice, dark-adapted ERGs were minimal following the first intravitreal injection of scAAV5-smCBA-RPE65. Following subsequent subretinal injection in the partner eye, dramatic ERG restoration was recorded in that eye. In fact, ERG b-wave amplitudes were statistically similar to those from the eyes that received the initial subretinal injection at a similar age. In C57BL/6J mice, GFP positive cells were detected in eyes following the first intravitreal injection around the injection site. Strong GFP expression in both the retinal pigment epithelium (RPE) and photoreceptor (PR) cells was detected in the partner eyes following the subsequent subretinal injection. Immunostaining of retinal sections with anti-RPE65 antibody showed strong RPE65 expression mainly in the RPE cells of subretinally injected eyes but not in the intravitreally injected eyes except minimally around the injection site. Conclusions: These results show that an initial intravitreal injection of AAV vectors to one eye of a mouse does not influence AAV-mediated gene expression or related therapeutic effects in the other eye when vectors are administered to the subretinal space. This suggests that the subretinal space possesses a unique immune privilege relative to the vitreous cavity.

AAV5-mediated Sflt01 Gene Therapy Arrests Retinal Lesions in Ccl2−/−/Cx3cr1−/− Mice

Suppression of matrigel-induced choroidal neovascularization by AAV delivery of a novel anti-Scg3 antibody

Scaav2-Mediated C3 Transferase Gene Therapy in a Rat Model with Retinal Ischemia/Reperfusion Injuries

Functional expression of complement factor I following AAV-mediated gene delivery in the retina of mice and human cells

Stable Inhibition of Choroidal Neovascularization by Adeno-Associated Virus 2/8-Vectored Bispecific Molecules

Lentiviral vector-mediated expression of C3 transferase attenuates retinal ischemia and reperfusion injury in rats

Timing of Antioxidant Gene Therapy: Implications for Treating Dry AMD

The Antiangiogenic Effect of Sanguinarine Chloride on Experimental Choroidal Neovacularization in Mice via Inhibiting Vascular Endothelial Growth Factor

Chimpanzee adenovirus-mediated multiple gene therapy for age-related macular degeneration

Unlocking therapeutic potential: dual gene therapy for ameliorating the disease phenotypes in a mouse model of RPE65 Leber congenital amaurosis

Effective AAV-mediated gene replacement therapy in retinal organoids modelling AIPL1-associated LCA4

Inactivation of Adenosine Receptor 2A Suppresses Endothelial-to-mesenchymal Transition and Inhibits Subretinal Fibrosis in Mice

Vitreal Delivery of AAV Vectored Cnga3 Restores Cone Function in CNGA3-/-/Nrl-/- Mice, an All-Cone Model of CNGA3 Achromatopsia.

AAV-Based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances in Age-Related Macular Degeneration and Diabetic Retinopathy Therapies

Low-Dose Recombinant Adeno-Associated Virus-Mediated Inhibition of Vascular Endothelial Growth Factor Can Treat Neovascular Pathologies Without Inducing Retinal Vasculitis

AAV-Mediated EPO Gene Reduction Inhibits Choroidal Neovascularization

Differential Proteomics And Functional Research Following Gene Therapy In A Mouse Model Of Leber Congenital Amaurosis

Gene augmentation therapy to rescue degenerative photoreceptors in a Cwc27 mutant mouse model

AAV2-PDE6B restores retinal structure and function in the retinal degeneration 10 mouse model of retinitis pigmentosa by promoting phototransduction and inhibiting apoptosis

A drug-tunable Flt23k gene therapy for controlled intervention in retinal neovascularization

Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye